ASKA Pharmaceutical Co., Ltd. Stock Japan Exchange
Stocks
4514
JP3541200006
Pharmaceuticals
OTC Markets Traded| Market Cap | 61.59B 391M 342M 321M 293M 551M 37.41B 551M 3.86B 1.49B 19.11B 1.47B 1.44B | P/E 2027 * |
13.2x | P/E 2028 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 61.59B 391M 342M 321M 293M 551M 37.41B 551M 3.86B 1.49B 19.11B 1.47B 1.44B | EV / Sales 2027 * |
0.84x | EV / Sales 2028 * | 0.82x |
| Free-Float |
64.59% | Yield 2027 * |
3% | Yield 2028 * | 3.23% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tomohito Nagao
CEO | Chief Executive Officer | - | - |
Sota Yamaguchi
PSD | President | 42 | 2025-06-23 |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 2025-06-23 | |
Atsushi Maruo
BRD | Director/Board Member | 67 | 2021-03-31 |
Sota Yamaguchi
BRD | Director/Board Member | 42 | 2021-03-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -4.29% | - | - | 391M | |
| +0.45% | +3.00% | +55.00% | +112.54% | 1,043B | |
| -0.10% | +0.74% | +54.52% | +67.72% | 649B | |
| +0.28% | +0.82% | +19.15% | +73.63% | 469B | |
| -0.19% | +0.97% | +34.30% | +45.99% | 355B | |
| +0.28% | +2.30% | +18.47% | +26.67% | 270B | |
| +0.89% | +4.59% | +10.19% | +14.72% | 262B | |
| +4.34% | +9.21% | +43.44% | +53.25% | 222B | |
| +1.40% | +4.35% | +35.72% | +103.53% | 189B | |
| -0.46% | -6.20% | -32.46% | -59.65% | 175B | |
| Average | +0.65% | +2.20% | +26.48% | +48.71% | 403.67B | |
| Weighted average by Cap. | +0.49% | +2.19% | +36.40% | +67.20% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 73.12B 465M 406M 382M 348M 654M 44.42B 654M 4.58B 1.77B 22.68B 1.74B 1.71B | 74.96B 476M 416M 391M 357M 670M 45.53B 670M 4.69B 1.81B 23.25B 1.79B 1.75B |
| Net income | 4.67B 29.67M 25.93M 24.37M 22.24M 41.73M 2.84B 41.74M 292M 113M 1.45B 111M 109M | 5.52B 35.1M 30.67M 28.83M 26.31M 49.37M 3.36B 49.38M 346M 134M 1.71B 132M 129M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
